Gross margin is expected to be approximately 72% for the third quarter of 2025, compared to 64% in the prior year period. “During the third quarter, we achieved new highs in terms of both TULSA-PRO installed base growth and existing system utilization, driving record total revenues,” commented Arun Menawat, CEO. “Our TULSA-PRO installed base now sits at 67 – up from 60 – and, due to our strong and growing capital sales pipeline, we continue to expect to reach at least 75 by the end of the year.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROF:
- Profound Medical Expands TULSA Program in Texas, Enhancing Prostate Treatment Access
- Profound Medical announces launch of TULSA by Texas Prostate, Dallas Medical
- Profound Medical’s Earnings Call: A Balanced Outlook
- Profound Medical to Participate in Lake Street’s BIG9 Conference
- Profound Medical Reports Q2 2025 Growth and New Innovations in Prostate Treatment